Approval · Notice of Compliance 20302 · 2018
OZEMPIC: Notice of Compliance 20302
Issued January 4, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20302
- Date
- January 4, 2018
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- SEMAGLUTIDE 1.34 MG per ML
- SEMAGLUTIDE 1.34 MG per PEN